Posted by Michael Wonder on 20 Oct 2022
AbbVie's Skyrizi (risankizumab) receives Health Canada approval as the first and only specific interleukin-23 to treat moderately to severely active Crohn's disease in adults
20 October 2022 - Third approved indication for Skyrizi (rizankizumab) is supported by safety and efficacy data from two induction and one maintenance Phase 3 clinical trials: ADVANCE, MOTIVATE and FORTIFY.
AbbVie today announced Health Canada approval for Skyrizi (risankizumab 600 mg intravenous induction at Week 0, Week 4 and Week 8, followed by 360 mg subcutaneous injection maintenance at Week 12 and every eight weeks thereafter) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies.
